3.02
price down icon0.66%   -0.02
after-market アフターアワーズ: 3.02
loading
前日終値:
$3.04
開ける:
$3.02
24時間の取引高:
215.73K
Relative Volume:
0.63
時価総額:
$208.34M
収益:
-
当期純損益:
$-29.07M
株価収益率:
-9.7419
EPS:
-0.31
ネットキャッシュフロー:
$-31.85M
1週間 パフォーマンス:
-1.95%
1か月 パフォーマンス:
+0.00%
6か月 パフォーマンス:
+0.00%
1年 パフォーマンス:
+88.75%
1日の値動き範囲:
Value
$2.86
$3.05
1週間の範囲:
Value
$2.86
$3.15
52週間の値動き範囲:
Value
$0.97
$4.00

Trevi Therapeutics Inc Stock (TRVI) Company Profile

Name
名前
Trevi Therapeutics Inc
Name
セクター
Healthcare (1182)
Name
電話
203-304-2499
Name
住所
195 CHURCH STREET, NEW HAVEN, CT
Name
職員
26
Name
Twitter
@TreviThera
Name
次回の収益日
2024-11-06
Name
最新のSEC提出書
Name
TRVI's Discussions on Twitter

Trevi Therapeutics Inc Stock (TRVI) Upgrades & Downgrades

日付 アクション アナリスト 評価の変更
2023-04-12 開始されました B. Riley Securities Buy
2022-11-22 開始されました SVB Leerink Outperform
2019-06-03 開始されました BMO Capital Markets Outperform
2019-06-03 開始されました Needham Buy
2019-06-03 開始されました SVB Leerink Outperform
2019-06-03 開始されました Stifel Buy
すべてを表示

Trevi Therapeutics Inc (TRVI) 最新ニュース

pulisher
Nov 04, 2024

Trevi Therapeutics to Report Third Quarter 2024 Financial Result - GuruFocus.com

Nov 04, 2024
pulisher
Oct 31, 2024

Trevi Therapeutics (TRVI) Set to Announce Earnings on Wednesday - MarketBeat

Oct 31, 2024
pulisher
Oct 30, 2024

Trevi Therapeutics to Report Third Quarter 2024 Financial Results and Provide a Corporate Update on November 6, 2024 - StreetInsider.com

Oct 30, 2024
pulisher
Oct 30, 2024

Trevi Therapeutics Adds Clinical Development Expertise in Chroni - GuruFocus.com

Oct 30, 2024
pulisher
Oct 23, 2024

Rosalind Advisors, Inc. Reduces Stake in Trevi Therapeutics Inc. - Yahoo Finance

Oct 23, 2024
pulisher
Oct 22, 2024

Trevi Therapeutics shares retain buy rating on Haduvio prospects By Investing.com - Investing.com UK

Oct 22, 2024
pulisher
Oct 22, 2024

Trevi Therapeutics (NASDAQ:TRVI) Given "Buy" Rating at HC Wainwright - MarketBeat

Oct 22, 2024
pulisher
Oct 21, 2024

Trevi Therapeutics completes enrollment for Phase 2a trial - Investing.com

Oct 21, 2024
pulisher
Oct 21, 2024

Trevi Therapeutics completes enrollment for Phase 2a trial By Investing.com - Investing.com Australia

Oct 21, 2024
pulisher
Oct 21, 2024

Trevi Therapeutics, Inc. Completes Enrollment in the Phase 2A RIVER Trial of Haduvio - Marketscreener.com

Oct 21, 2024
pulisher
Oct 21, 2024

Trevi Therapeutics Completes Enrollment for Phase 2a RIVER Trial in Refractory Chronic Cough - Citizentribune

Oct 21, 2024
pulisher
Oct 19, 2024

Trevi Therapeutics, Inc. (NASDAQ:TRVI) Receives Consensus Recommendation of "Buy" from Analysts - MarketBeat

Oct 19, 2024
pulisher
Oct 18, 2024

TSX Global Gold Index (TTGD) QuotePress Release - The Globe and Mail

Oct 18, 2024
pulisher
Oct 18, 2024

Leerink Partnrs Has Negative Outlook of TRVI FY2024 Earnings - MarketBeat

Oct 18, 2024
pulisher
Oct 15, 2024

Trevi Therapeutics to Participate in Upcoming Commercial and Investor Conferences - Citizentribune

Oct 15, 2024
pulisher
Oct 09, 2024

Trevi Therapeutics Inc (TRVI) Q2 2024 Earnings Call Highlights: Navigating Financial Challenges ... - Yahoo Finance

Oct 09, 2024
pulisher
Oct 09, 2024

Trevi Therapeutics Inc (TRVI) Q2 2024 Earnings Call Highlights: - GuruFocus.com

Oct 09, 2024
pulisher
Oct 08, 2024

Oppenheimer maintains Outperform on Trevi Therapeutics on Haduvio potential By Investing.com - Investing.com Canada

Oct 08, 2024
pulisher
Oct 07, 2024

Trevi Therapeutics' (TRVI) Buy Rating Reaffirmed at B. Riley - MarketBeat

Oct 07, 2024
pulisher
Oct 04, 2024

Trevi Therapeutics reports progress in clinical trials - Investing.com

Oct 04, 2024
pulisher
Oct 04, 2024

Trevi Therapeutics (NASDAQ:TRVI) Given "Buy" Rating at Needham & Company LLC - MarketBeat

Oct 04, 2024
pulisher
Oct 04, 2024

Trevi updates on clinical progress for chronic cough treatment - The Pharma Letter

Oct 04, 2024
pulisher
Oct 04, 2024

Trevi Therapeutics reports progress in clinical trials By Investing.com - Investing.com UK

Oct 04, 2024
pulisher
Oct 04, 2024

Trevi Therapeutics, Inc. Announces Updates on Its Clinical Development Programs - Marketscreener.com

Oct 04, 2024
pulisher
Oct 04, 2024

Trevi Therapeutics hits 50% enrollment in IPF cough study By Investing.com - Investing.com South Africa

Oct 04, 2024
pulisher
Oct 03, 2024

Trevi Therapeutics hits 50% enrollment in IPF cough study - Investing.com India

Oct 03, 2024
pulisher
Oct 03, 2024

Trevi Therapeutics Provides Update on Haduvio's Clinical Development Program - Kilgore News Herald

Oct 03, 2024
pulisher
Sep 30, 2024

Trevi Therapeutics Announces Appointment of James V. Cassella, Ph.D., as Chief Development Officer - The Malaysian Reserve

Sep 30, 2024
pulisher
Sep 27, 2024

President & CEO GOOD JENNIFER L sale 4,219 shares of Trevi Therapeutics Inc [TRVI] - Knox Daily

Sep 27, 2024
pulisher
Sep 26, 2024

Trevi Therapeutics Announces Additional Analyses of Cough Relief Time from Ph2a CANAL Trial Accepted for Oral Presentation at CHEST 2024 - StockTitan

Sep 26, 2024
pulisher
Sep 24, 2024

Logos Global Management LP Purchases 600,000 Shares of Trevi Therapeutics, Inc. (NASDAQ:TRVI) - MarketBeat

Sep 24, 2024
pulisher
Sep 24, 2024

Trevi Therapeutics, Inc. (NASDAQ:TRVI) Given Average Rating of "Buy" by Analysts - MarketBeat

Sep 24, 2024
pulisher
Sep 23, 2024

Financial Health Report: Trevi Therapeutics Inc (TRVI)’s Ratios Tell a Tale - The Dwinnex

Sep 23, 2024
pulisher
Sep 23, 2024

Ally Bridge Group NY LLC Invests $4.40 Million in Trevi Therapeutics, Inc. (NASDAQ:TRVI) - MarketBeat

Sep 23, 2024
pulisher
Sep 23, 2024

Taking the lead: Trevi Therapeutics Inc (TRVI) - SETE News

Sep 23, 2024
pulisher
Sep 21, 2024

Trevi Therapeutics (TRVI) 10K Form and SEC Filings 2024 - MarketBeat

Sep 21, 2024
pulisher
Sep 19, 2024

Traws Pharma Inc. (TRAW) Stock: A Comprehensive 52-Week Review - The InvestChronicle

Sep 19, 2024
pulisher
Sep 18, 2024

Portage Biotech (PRTG): Wild Ride Continues, But Uncertainty Looms - BP Journal

Sep 18, 2024
pulisher
Sep 18, 2024

Tourmaline Bio (NASDAQ:TRML) Shares Up 3.9% - Defense World

Sep 18, 2024
pulisher
Sep 18, 2024

UChicago Medicine Patient First in the World to Re | Newswise - Newswise

Sep 18, 2024
pulisher
Sep 17, 2024

Traws Pharma Announces Stock Split, Share Adjustments, and Growth Strategy - TipRanks

Sep 17, 2024
pulisher
Sep 17, 2024

UChicago Medicine patient first in the world to receive ulcerative colitis drug since FDA approval - UChicago Medicine

Sep 17, 2024
pulisher
Sep 17, 2024

Traws Pharma, Inc. Announces Special Shareholders Meeting Results - StockTitan

Sep 17, 2024
pulisher
Sep 17, 2024

Taking a Closer Look At Trevi Therapeutics Inc (TRVI) Following Its Recent Trade - Knox Daily

Sep 17, 2024
pulisher
Sep 17, 2024

trivago (NASDAQ:TRVG) Sees Large Growth in Short Interest - Defense World

Sep 17, 2024
pulisher
Sep 17, 2024

FDA Approves Tremfya for Ulcerative Colitis - Physician's Weekly

Sep 17, 2024
pulisher
Sep 15, 2024

Trevi Therapeutics to Report Q1 2023 Financial Results and Provide a Corporate Update on May 11, 2023 - Quantisnow

Sep 15, 2024
pulisher
Sep 15, 2024

trivago (NASDAQ:TRVG) Short Interest Up 16.9% in August - MarketBeat

Sep 15, 2024
pulisher
Sep 11, 2024

Trevi Therapeutics, Inc. to Post Q3 2024 Earnings of ($0.12) Per Share, Leerink Partnrs Forecasts (NASDAQ:TRVI) - MarketBeat

Sep 11, 2024
pulisher
Sep 10, 2024

Trevi Therapeutics, Inc. Expected to Earn Q1 2025 Earnings of ($0.11) Per Share (NASDAQ:TRVI) - MarketBeat

Sep 10, 2024
pulisher
Sep 10, 2024

Leerink Partnrs Upgrades Trevi Therapeutics (NASDAQ:TRVI) to "Strong-Buy" - MarketBeat

Sep 10, 2024

Trevi Therapeutics Inc (TRVI) 財務データ

収益

loading

当期純利益

loading

現金流量

loading

EPS

loading

Trevi Therapeutics Inc (TRVI) インサイダートレーディング

インサイダートレーディング 関係 日付 取引 コスト #株式 値 ($) #株式総数
GOOD JENNIFER L
President & CEO
Sep 09 '24
Option Exercise
1.43
1,840
2,631
215,153
GOOD JENNIFER L
President & CEO
Sep 06 '24
Sale
3.03
4,219
12,784
213,313
GOOD JENNIFER L
President & CEO
Sep 09 '24
Sale
3.04
1,840
5,587
213,313
GOOD JENNIFER L
President & CEO
Sep 05 '24
Option Exercise
1.43
40,277
57,596
253,590
GOOD JENNIFER L
President & CEO
Sep 04 '24
Option Exercise
1.43
10,981
15,703
224,294
GOOD JENNIFER L
President & CEO
Sep 03 '24
Option Exercise
1.43
3,863
5,524
217,176
GOOD JENNIFER L
President & CEO
Sep 05 '24
Sale
3.11
40,277
125,310
213,313
GOOD JENNIFER L
President & CEO
Sep 04 '24
Sale
3.02
10,981
33,205
213,313
GOOD JENNIFER L
President & CEO
Sep 03 '24
Sale
3.02
3,863
11,677
213,313
$77.28
price up icon 2.02%
$20.39
price up icon 2.15%
$382.77
price up icon 1.58%
$53.29
price down icon 0.47%
$208.03
price up icon 0.38%
$110.97
price up icon 1.84%
大文字化:     |  ボリューム (24 時間):